Identification of the first-in-class dual inhibitors of human DNA topoisomerase IIα and indoleamine-2,3-dioxygenase 1 (IDO 1) with strong anticancer properties

References

• [accessed 23 May 2022] https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• [accessed 23 May 2022] https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf
   Google Scholar
• Dalmartello M, La Vecchia C, Bertuccio P, Boffetta P, Levi F, Negri E, Malvezzi M. European cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann Oncol. 2022;33(3):330–339.
   PubMed Web of Science ®Google Scholar
• [accessed 23 May 2022] https://www.nih.gov/news-events/news-releases/cancer-costs-projected-reachleast-158-billion-2020
   Google Scholar
• Nittis JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009; 9:338–350.
   PubMed Web of Science ®Google Scholar
• Siwek A, Stączek P, Wujec M, Bielawski K, Bielawska A, Paneth P. Cytotoxic effect and molecular docking of 4-ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemicarbazide – a novel topoisomerase II inhibitor. J Mol Model. 2013;19(3):1319–1324.
   PubMed Web of Science ®Google Scholar
• Siwek A, Bielawska A, Maciorkowska E, Lepiarczyk M, Bielawski K, Trotsko N, Wujec M. Cytotoxicity and topoisomerase I/II inhibition activity of novel 4- aryl/alkyl-1-(piperidin-4-yl)-carbonylthiosemicarbazides and 4- benzoylthiosemicarbazides. J Enzyme Inhib Med Chem. 2014;29(2):243–248.
   PubMed Web of Science ®Google Scholar
• Kapron B, Czarnomysy R, Paneth A, Wujec M, Bielawski K, Bielawska A, Swiatek L, Rajtar B, Polz-Dacewicz M, Plech T, et al. Dual antibacterial and anticancer activity of 4-benzoyl-1-dichlorobenzoylthiosemicarbazide derivatives. Anticancer Agents Med Chem. 2018;18(4):529–540.
   PubMed Web of Science ®Google Scholar
• Malki A, Elbayaa RY, Ashour HMA, Loffredo CA, Youssef AM. Novel thiosemicarbazides induced apoptosis in human MCF-7 breast cancer cells via JNK signaling. J Enzyme Inhib Med Chem. 2015;30(5):786–795.
   PubMed Web of Science ®Google Scholar
• Laxmi SV, Rajitha G, Rajitha B, Rao AJ. Photochemical synthesis and anticancer activity of barbituric acid, thiobarbituric acid, thiosemicarbazide, and isoniazid linked to 2-phenyl indole derivatives. J Chem Biol. 2016;9(2):57–63.
   PubMedGoogle Scholar
• Kalinowski DS, Quach P, Richardson DR. Thiosemicarbazones: the new wave in cancer treatment. Future Med Chem. 2009;1(6):1143–1151.
   PubMed Web of Science ®Google Scholar
• Moorthy NSHN, Cerqueira NMFSA, Ramos MJ, Fernandes PA. QSAR and pharmacophore analysis of thiosemicarbazone derivatives as ribonucleotide reductase inhibitors. Med Chem Res. 2012;21(6):739–746.
   Web of Science ®Google Scholar
• Graser-Loescher G, Schoenhuber A, Ciglenec C, Eberl S, Krupitza G, Mader RM, Jadav SS, Jayaprakash V, Fritzer-Szekeres M, Szekeres T, et al. Thiosemicarbazone derivatives, thiazolyl hydrazones, effectively inhibit leukemic tumor cell growth: down-regulation of ribonucleotide reductase activity and synergism with arabinofuranosylcytosine. Food Chem Toxicol. 2017;108(Pt A):53–62.
   PubMedGoogle Scholar
• Plech T, Wujec M, Siwek A, Kosikowska U, Malm A. Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3- chlorophenyl moiety. Eur J Med Chem. 2011;46(1):241–248.
   PubMed Web of Science ®Google Scholar
• Serra S, Moineaux L, Vancraeynest C, Masereel B, Wouters J, Pochet L, Frédérick R. Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties. Eur J Med Chem. 2014;82:96–105.
   PubMed Web of Science ®Google Scholar
• Röhrig UF, Majjigapu SR, Vogel P, Zoete V, Michielin O. Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. J Med Chem. 2015;58(24):9421–9437.
   PubMed Web of Science ®Google Scholar
• Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer. 2017;76:167–182.
   PubMed Web of Science ®Google Scholar
• Hornyák L, Dobos N, Koncz G, Karányi Z, Páll D, Szabó Z, Halmos G, Székvölgyi L. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. 2018;9(151):151.
   PubMedGoogle Scholar
• Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang S, Li Y. Targeting the IDO1 pathway in cancer: from bench to bedside. J Hematol Oncol. 2018;11(1):100.
   PubMedGoogle Scholar
• Ishida Y. PD-1: Its discovery, involvement in cancer immunotherapy, and beyond. Cells. 2020;9(6):1376.
   PubMed Web of Science ®Google Scholar
• Grubczak K, Kretowska-Grunwald A, rowth D, Poplawska I, Eljaszewicz A, Bolkun L, Starosz A, Holl JM, Mysliwiec M, Kruszewska J, et al. Differential response of MDA-MB-231 and MCF-7 breast cancer cells to in vitro inhibition with CTLA-4 and PD-1 through cancer-immune cells modified interactions. Cells. 2021;10(8):2044.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.
   PubMed Web of Science ®Google Scholar
• www.IC50.tk
   Google Scholar